摘要
目的探讨氟哌噻吨美利曲辛联合莫沙必利、泮托拉唑在功能性消化不良(FD)治疗中的应用效果。方法以我院收治的108例FD患者为研究对象,根据随机数字表法将患者分为对照组和研究组,各54例。对照组联合应用莫沙必利与泮托拉唑治疗,研究组在对照组基础上联合氟哌噻吨美利曲辛治疗。比较两组患者的临床疗效、治疗前后临床症状评分及不良反应发生率。结果研究组的治疗总有效率高于对照组(P<0.05)。治疗后,两组的餐后饱胀、早饱感、上腹疼痛或不适、上腹烧灼感评分均较治疗前明显降低,且研究组显著优于对照组(P<0.05)。两组的不良反应发生率无显著差异(P>0.05)。结论氟哌噻吨美利曲辛联合莫沙必利、泮托拉唑可有效改善FD患者的临床症状,疗效显著,且不增加不良反应,值得临床推广。
Objective To explore application effect of flupentixol and melitracen combined with mosapride and pantoprazole in the treatment of functional dyspepsia(FD). Methods The clinical data of 108 patients with FD in our hospital were studied, the patients were divided into control group and study group according to the random number table, with 54 cases in each group. The control group was treated with mosapride and pantoprazole. The study group was treated with flupentixol and melitracen on the basis of the control group. The clinical efficacy, clinical symptom scores before and after treatment and incidence of adverse reactions were compared between the two groups. Results The total effective rate of the study group was higher than that of the control group(P<0.05). After treatment, the scores of postprandial fullness, early satiety,abdominal pain or discomfort and upper abdominal burning sensation in both groups were significantly lower than those before treatment, and those of the study group were significantly better than the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion Flupentixol and melitracen combined with mosapride and pantoprazole in the treatment of FD can improve the patients' clinical symptom, with significant effect, and does not increase adverse reactions, whcih is worth clinical promotion.
出处
《临床医学研究与实践》
2018年第7期20-21,共2页
Clinical Research and Practice
